SCHEMBL5496992

SCHEMBL5496992

CC(C)(C)OC(=O)CC(NC(=O)C1CCCCN1C(=O)OCc1ccccc1)C(O)CF

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTRB1 P17538 1/20 0.52
KMT2A Q03164 2/20 0.49
CTSK P43235 3/20 0.47
CTSB P07858 1/20 0.47
CTSS P25774 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TSHR P16473 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
KDM4E B2RXH2 1/20 0.47
LMNA P02545 1/20 0.47
GFER P55789 1/20 0.46
CTSL P07711 1/20 0.46
KLK5 Q9Y337 1/20 0.46
ALDH1A1 P00352 1/20 0.46
FKBP1A P62942 1/20 0.45
PREP P48147 1/20 0.45
CMA1 P23946 1/20 0.45
TP53 P04637 1/20 0.45
MEN1 O00255 1/20 0.45
KLK7 P49862 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5496996 1.00 CTRB1 (0.52) CTRB1KMT2ACTSKCTSBCTSS
SCHEMBL7167010 0.86 CTRB1 (0.53) CTRB1KMT2ACTSKCTSBCTSS
SCHEMBL7167015 0.86 CTRB1 (0.53) CTRB1KMT2ACTSKCTSBCTSS
SCHEMBL993938 0.84 TSHR (0.56) CTRB1KMT2ACTSKNPSR1TSHR
SCHEMBL8289059 0.84 TSHR (0.56) CTRB1KMT2ACTSKNPSR1TSHR
SCHEMBL12950181 0.82 CTRB1 (0.61) CTRB1KMT2ACTSKNPSR1TSHR
SCHEMBL992994 0.82 CTRB1 (0.64) CTRB1KMT2ACTSKNPSR1TSHR
SCHEMBL8287761 0.82 CTRB1 (0.64) CTRB1KMT2ACTSKNPSR1TSHR
SCHEMBL994089 0.81 CTRB1 (0.58) CTRB1KMT2ACTSKNPSR1TSHR
SCHEMBL8287700 0.81 CTRB1 (0.58) CTRB1KMT2ACTSKNPSR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010457-A1 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2007-01-11 US disclosed
EP-1381602-A1 HETEROCYCLYLDICARBAMIDES AS CASPASE INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2004-01-21 EP disclosed
US-20030096737-A1 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2003-05-22 US disclosed
WO-2002085899-A1 HETEROCYCLYLDICARBAMIDES AS CASPASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096737-A1 Caspase inhibitors and uses thereof CASP1, APAF1, CASP5 CTRB1 671/4885KMT2A 4582/4885CTSK 172/4885
US-20070010457-A1 Caspase inhibitors and uses thereof CASP1, APAF1, TNF CTRB1 807/4885KMT2A 4426/4885CTSK 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.